EphB receptor-binding peptides
View Patent ↗The application is related to the identification of peptides that selectively bind to Eph receptors of the B class. Also disclosed are uses of such peptides in the treatment of a variety of diseases. Additionally, imaging tumors in patients is described by administrating labeled peptides to patients and then obtaining an image of the labeled peptides.
1. An isolated peptide which binds to a member of EphB1 or EphB2 receptor and inhibits binding of Ephrin B ligand to said member of the EphB1 or EphB2 receptor, wherein said peptide consists of less than 25 amino acid residues and has the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5.
2. The isolated peptide of claim 1 , wherein said peptide has the amino acid sequence of SEQ ID NO: 1 and selectively binds to EphB1.
3. The isolated peptide of claim 1 , wherein said peptide has the amino acid sequence of SEQ ID NO: 2 and selectively binds to EphB1.
4. The isolated peptide of claim 1 , wherein said peptide has the amino acid sequence of SEQ ID NO: 3 and selectively binds to EphB1.
5. The isolated peptide of claim 1 , wherein said peptide has the amino acid sequence of SEQ ID NO: 4 and binds to EphB1 or EphB2.
6. The isolated peptide of claim 1 , wherein said peptide has the amino acid sequence of SEQ ID NO: 5 and binds to EphB1 or EphB2.
7. The isolated peptide of claim 1 , in association with a therapeutically acceptable carrier.
8. The isolated peptide of claim 1 , wherein said peptide consists of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5.
9. The isolated peptide of claim 2 , wherein said peptide inhibits Ephrin B2 ligand binding to the EphB1 receptor with an IC 50 value of approximately 10 μM.
10. The isolated peptide of claim 4 , wherein said peptide inhibits Ephrin B2 ligand binding to the EphB1 receptor with an IC 50 value of approximately 150 μM.
11. The isolated peptide of claim 9 or 10 , wherein the IC 50 value is determined by assays to measure the concentration of said peptide necessary to inhibit binding by 50% of alkaline phosphatase-tagged Ephrin B2 ligand to an ectodomain of the EphB1 receptor, wherein alkaline phosphatase-tagged Ephrin B2 ligand binding to the ectodomain of the EphB1 receptor is detected by measuring alkaline phosphatase activity.
12. A conjugate comprising the peptide of claim 1 or claim 8 and a therapeutic agent or imaging agent.
13. The conjugate of claim 12 , wherein said therapeutic agent is a chemotherapeutic agent, a toxin, a radioactive molecule, a clotting protein, an immunosuppressive agent, or a hormone.
14. The conjugate of claim 12 , wherein said peptide and said therapeutic agent or said imaging agent are conjugated to each other via a linker.
15. The conjugate of claim 12 , wherein said imaging agent is a radionuclide or a fluorescent label.